Study Report
Reference
| Citation | Piletz, 2010 PubMed |
| Full Info | Piletz, J.E., Halaris, A., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J. and Devane, C.L. (2009) Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry, 10, 313-323.
|
Study
| Hypothesis or Background |
High levels of pro-inflammatory biomarkers have been reported in depression.
|
| Sample Information | patients with major depressive disorder (MDD)and age- and sex-matched healthy subjects |
|---|
| Method Detail | n the present study, five pro-inflammatory biomarkers were measured in the blood of patients with major depressive disorder (MDD). Biomarker levels were compared to age- and sex-matched healthy subjects |
| Method Keywords | protein analysis |
| Result | Patients with MDD had significantly higher baseline levels of tumour necrosis factor-alpha (TNFalpha, P=0.04), interleukin-1beta (IL1beta, P=0.03), and monocyte chemotactic protein-1 (MCP-1; P=0.02) compared to controls. There were no differences between groups in levels of cell determinant-40 ligand (CD40L) and C-reactive protein (CRP). A subset of the MDD patients consented to undergo treatment with venlafaxine (an SNRI: at lower doses a selective serotonin reuptake inhibitor; at higher doses also a norepinephrine reuptake inhibitor) for 8 weeks. By week 8, all treatment completers had responded therapeutically. However, levels of TNFalpha, IL1beta, and MCP-1 remained elevated. |
| Conclusions | A concave quadratic equation described the associations between plasma venlafaxine concentrations and IL1beta (P=0.03), TNFalpha (P=0.09), and MCP-1 (P=0.02), suggesting that these biomarkers may have become selectively lowered in the serotonergic dose range of venlafaxine. This is the first report of venlafaxine's possible effect on pro-inflammatory biomarkers. |
Relationships reported by
Piletz, 2010
| Component A Approved Name (Name in Paper) |
Component A Type |
Component B Approved Name (Name in Paper) |
Component B Type |
Statistical Result |
Relationship Description |
Result Category (Positive/Negative)) |
|
MDD
|
syndrome |
Interleukin-1 beta (IL1-¦Â) |
protein |
P-value=0.03 |
Compared to controls, patients with MDD had significantly higher baseline levels of interleukin-1beta (IL1beta, P=0.03) in the blood. |
Positive
|
|
MDD
|
syndrome |
C-C motif chemokine 2 (MCP-1) |
protein |
P-value=0.02 |
Compared to controls, patients with MDD had significantly higher baseline levels of monocyte chemotactic protein-1 (MCP-1; P=0.02) in the blood. |
Positive
|
|
MDD
|
syndrome |
Tumor necrosis factor (TNF-¦Á) |
protein |
P-value=0.04 |
Compared to controls, patients with MDD had significantly higher baseline levels of tumour necrosis factor-alpha (TNFalpha, P=0.04) in the blood. |
Positive
|
